topiramate

Phase 2Completed

1 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Epilepsy, Absence

Conditions

Epilepsy, Absence

Trial Timeline

Mar 1, 2005 → Oct 1, 2006

NCT ID

NCT00210574

About topiramate

topiramate is a phase 2 stage product being developed by Johnson & Johnson for Epilepsy, Absence. The current trial status is completed. This product is registered under clinical trial identifier NCT00210574. Target conditions include Epilepsy, Absence.

What happened to similar drugs?

20 of 20 similar drugs in Epilepsy, Absence were approved

Approved (20) Terminated (6) Active (0)

✅ZonegranEisaiApproved

✅Perampanel + PlaceboEisaiApproved

✅perampanelEisaiApproved

✅Perampanel Oral TabletEisaiApproved

✅PerampanelEisaiApproved

✅zonisamide low dose group + zonisamide high dose groupEisaiApproved

✅Zonisamide at targeted daily doses of 100-500 mg/day + Placebo administered to match targeted daily doses of 100-500 mg/dayEisaiApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00223626	Phase 2	Completed	Jan 1, 2007	Dec 1, 2010	Cocaine-Related Disorders
NCT00266604	Approved	Completed	Dec 1, 2005	Jun 1, 2007	Epilepsy
NCT00223639	Phase 2	Completed	Sep 1, 2005	Jul 1, 2008	Alcoholism
NCT00233012	Phase 1	Completed	Jun 1, 2005	Oct 1, 2007	Seizures
NCT00210574	Phase 2	Completed	Mar 1, 2005	Oct 1, 2006	Epilepsy, Absence
NCT00210860	Phase 3	Completed	Sep 1, 2004	Mar 1, 2006	Migraine
NCT00210925	Phase 2	Completed	Mar 1, 2004	Aug 1, 2006	Alcoholism
NCT00231647	Phase 2	Completed	Feb 1, 2004	Oct 1, 2004	Obesity
NCT00210821	Phase 3	Completed	Feb 1, 2004	Nov 1, 2005	Migraine
NCT00210873	Phase 3	Completed	Feb 1, 2004	Aug 1, 2005	Migraine
NCT00210808	Phase 2/3	Completed	Sep 1, 2003	Mar 1, 2005	Obesity
NCT00210912	Phase 3	Completed	Sep 1, 2003	Apr 1, 2005	Migraine
NCT00236496	Phase 3	Completed	Oct 1, 2001	Feb 1, 2004	Essential Tremor
NCT00035230	Phase 3	Completed	Jul 1, 2001	Nov 1, 2002	Bipolar Disorder
NCT00231673	Phase 2	Completed	Jul 1, 2001	Jan 1, 2003	Diabetic Neuropathies
NCT00231634	Phase 3	Terminated	May 1, 2001	Nov 1, 2002	Obesity
NCT00231621	Phase 3	Terminated	May 1, 2001	Jun 1, 2002	Obesity
NCT00231595	Phase 3	Completed	Mar 1, 2001	Nov 1, 2002	Migraine
NCT00236665	Phase 3	Completed	Mar 1, 2001	Jun 1, 2002	Obesity
NCT00236509	Phase 3	Completed	Feb 1, 2001	Sep 1, 2002	Migraine

Competing Products

20 competing products in Epilepsy, Absence

See all competitors

Product	Company	Stage	Hype Score
perampanel	Eisai	Phase 2	35
Lacosamide	UCB	Phase 3	40
Zonisamide + Placebo	Eisai	Phase 3	32
Zonegran	Eisai	Approved	35
perampanel + perampanel	Eisai	Phase 1	29
Perampanel + Placebo	Eisai	Approved	35
perampanel	Eisai	Approved	35
E2007 + Placebo	Eisai	Phase 2	35
Placebo + Rufinamide	Eisai	Phase 3	40
E2007 (perampanel) + Placebo	Eisai	Phase 2	35
Perampanel Oral Tablet	Eisai	Approved	43
perampanel	Eisai	Phase 3	40
Perampanel	Eisai	Pre-clinical	26
Zonisamide + Carbamazepine	Eisai	Phase 3	40
Perampanel	Eisai	Approved	43
Perampanel and Microgynon-30 + Perampanel and Microgynon-30	Eisai	Phase 1	29
Perampanel	Eisai	Phase 2	35
Zonisamide + Placebo	Eisai	Phase 3	40
zonisamide low dose group + zonisamide high dose group	Eisai	Approved	43
E2007 + E2007 + Placebo	Eisai	Phase 2	35